Ondine Biomedical Inc.

Regulatory Filings • Nov 21, 2022

National Storage Mechanism | Additional information

RNS Number : 9872G

Ondine Biomedical Inc.

21 November 2022

21 November 2022

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine appoints Spanish distributer for Steriwave

Canadian life sciences company Ondine Biomedical has appointed leading medical device distributer, Distrauma Medical SL, to distribute its Steriwave™ nasal photodisinfection in Spain. Distrauma, a national medical device supplier focusing on surgical equipment for hospitals, was founded in 1994 and is headquartered in Barcelona, Spain. The primary application for Steriwave nasal photodisinfection is nasal decolonization for the prevention of healthcare-associated infections, including surgical site infections.

Steriwave can eliminate nasal bacteria, viruses, and fungi with a simple, 5-minute, non-antibiotic treatment. The two-step process involves the application of a proprietary light-activated agent to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of laser light. The light activates the photodynamic agent, causing an oxidative burst that destroys all types of pathogens. A key benefit of this approach is that pathogens do not develop resistance to the therapy.

Steriwave has a CE mark for use in the EU and is approved in Canada, the UK, and several other countries.

Ondine Biomedical Inc.
Angelika Vance, Corporate Communications	+001 (1) 604 838 2702
Strand Hanson Limited (Nominated and Financial Adviser)
James Harris, James Dance, Richard Johnson	+44 (0) 20 7409 3494
RBC Capital Markets
Rupert Walford, Kathryn Deegan	+44 (0) 20 7653 4000
Singer Capital Markets
Aubrey Powell, Asha Chotai	+44 (0) 20 7496 3000
Vane Percy & Roberts (Media Contact)
Simon Vane Percy, Amanda Bernard	+44 (0) 77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADBBDBLUDDGDG